21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hyaluronidase inhibits reactive adipogenesis and inflammation of colon and skin

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this study we evaluated the role of hyaluronan (HA) in reactive adipogenesis, a local expansion of preadipocytes that provides host defense by release of antimicrobial peptides. We observed that HA accumulated during maturation of adipocytes in vitro and was associated with increased expression of preadipocyte factor 1, zinc finger protein 423, and early B cell factor 1. Although HA is normally abundant in the extracellular matrix, a further increase in HA staining occurred in mice at sites of reactive adipogenesis following injury of colon by dextran sodium sulfate or injury of skin from infection with Staphylococcus aureus. HA also abundantly accumulated around adipocytes seen in the colons of patients with inflammatory bowel disease. This HA was necessary for adipocyte maturation because digestion of HA by administration of soluble hyaluronidase or transgenic expression of hyaluronidase 1 inhibited adipogenesis in vitro and in vivo. Furthermore, hyaluronidase also suppressed inflammation of both skin and colon and decreased antimicrobial peptide expression by developing preadipocytes. This resulted in increased bacterial transit across the epithelial barrier despite decreased tissue injury from inflammation. These observations suggest HA plays an important role in reactive adipogenesis and host defense after injury.

          Abstract

          Abstract

          Hyaluronidase suppresses reactive adipogenesis, an innate immune defense mechanism for production of antimicrobial peptides.

          Related collections

          Author and article information

          Contributors
          Journal
          JCI Insight
          JCI Insight
          JCI Insight
          JCI Insight
          American Society for Clinical Investigation
          2379-3708
          2 November 2018
          2 November 2018
          2 November 2018
          : 3
          : 21
          : e123072
          Affiliations
          [1 ]Department of Dermatology, UCSD, La Jolla, California, USA.
          [2 ]Halozyme Therapeutics Inc., San Diego, California, USA.
          [3 ]Department of Legal Medicine, Asahikawa Medical University, Asahikawa, Japan.
          [4 ]Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
          Author notes
          Address correspondence to: Richard L. Gallo, Department of Dermatology, MC0869, University of California, San Diego, 9500 Gilman Dr, La Jolla, California, USA, 92093-0869. Phone: 858.822.4608; Email: rgallo@ 123456ucsd.edu .
          Author information
          http://orcid.org/0000-0002-6187-2991
          http://orcid.org/0000-0002-1401-7861
          Article
          PMC6238730 PMC6238730 6238730 123072
          10.1172/jci.insight.123072
          6238730
          30385720
          cfa11bfb-5f13-4be8-9d05-8fe9156a72f1
          Copyright © 2018, American Society for Clinical Investigation
          History
          : 21 June 2018
          : 13 September 2018
          Funding
          Funded by: NIH
          Award ID: NIH R01AR069653
          Award ID: R01AI052453,NIH P01HL107150
          Categories
          Research Article

          Dermatology,Inflammation,Adipose tissue,Defensins,Glycobiology

          Comments

          Comment on this article